荆花胃康胶丸联合双歧杆菌治疗幽门螺杆菌感染的回顾性研究

Retrospective study of Jinghua Weikang Capsule combined with bifidobacterium in treating Helicobacter pylori infection

关键词:  荆花胃康胶丸  双歧杆菌三联活菌  幽门螺杆菌  根除率  不良反应

Key words:  Jinghua Weikang Capsule  bifidobacterium  helicobacter pylori  eradication rate  adverse reaction

摘要:

[目的] 回顾性分析荆花胃康胶丸联合双歧杆菌治疗幽门螺杆菌（Hp）感染证属脾胃湿热证患者的临床疗效和安全性。[方法] 选取首都医科大学附属北京中医医院门诊Hp感染证属脾胃湿热证病例115例，将其按照治疗方案分为3组，分别为标准四联组（35例）、荆花胃康胶丸+标准四联组（42例）、荆花胃康胶丸+双歧杆菌组（38例）。治疗2周后，停药4周以上，进行¹³C或¹⁴C呼气复查。观察对比3组病例中医单项症状频次与频率、中医证候疗效评价、Hp根除率及服药后不良反应的情况。[结果] Hp感染患者中医单项症状频率，依次为上腹胀、上腹痛、口臭。荆花胃康胶丸联合双歧杆菌组根除率（68.42%）与标准四联（80.00%）比较，差异无统计学意义（P>0.05）。荆花胃康胶丸联合标准四联组根除率（92.86%）高于荆花胃康胶丸联合双歧杆菌组（P<0.01），差异有统计学意义；与标准四联组相比差异无统计学意义（P>0.05）。荆花胃康胶丸联合双歧杆菌组中医证候疗效评价、不良反应优于其他两组，差异有统计学意义（P<0.05）。[结论] 荆花胃康胶丸联合双歧杆菌能够在根除Hp的同时，兼顾改善患者临床症状，不良反应少。

Abstract:

[Objective] To evaluate the therapeutic effect of Jinghua Weikang Capsule combined with bifidobacterium on patients with helicobacter pylori （Hp） infection and identified with the dampness-heat syndrome in the spleen and stomach. [Methods] This study was a retrospective research based on a total of 115 patients who were admitted to The Digestion Center of Beijing Hospital of Traditional Chinese Medicine Attached to Capital Medical University，with Hp infection and identified with the dampness-heat syndrome in the spleen and stomach. Via different treatment methods，the patients were divided into three groups：quadruple therapy group（35 cases），Jinghua Weikang Capsule combined with quadruple therapy group （42 cases） and Jinghua Weikang Capsule combined with bifidobacterium therapy group （38 cases）. All cases were evaluated by ¹³C or ¹⁴C-urea breath test （UBT） after being treated for 14 days，with over 4 weeks long drug withdrawal. The single symptom frequency，therapeutic evaluation of clinical symptoms，eradication rate of helicobacter pylori and occurrence of adverse reactions were observed and assessed. [Results] For patients infected with Hp，the single symptom frequency was epigastric distention，epigastric pain and ozostomia in sequence. There was no significant statistical difference （P>0.05） in Hp eradication rate between the quadruple therapy group （80.00%） and the Jinghua Weikang Capsule combined with bifidobacterium therapy group （68.42%）. Hp eradication rate of Jinghua Weikang Capsule combined with quadruple therapy group （92.86%） was higher than that of Jinghua Weikang Capsule combined with bifidobacterium therapy group，with the significant statistical difference （P<0.01）；meanwhile，its Hp eradication rate was higher than that of quadruple therapy group，with no statistical difference （P>0.05）. As for the therapeutic evaluation of clinical symptoms and adverse reactions，the Jinghua Weikang Capsule combined with bifidobacterium therapy group was obviously superior to the other two groups，with the significant statistical difference （P<0.05）. [Conclusion] The therapy of Jinghua Weikang Capsule combined with bifidobacterium，characterized by highly complied and less adverse reactions，can eradicate Hp and is effective in improving clinical symptoms.